- Home
- /
- Treatment
- /
- Page 147
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
Country | Product | Indication | Sponsor | Date |
---|---|---|---|---|
Sargramostim | Neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment | Immunex Corporation;51 University Street;Seattle, WA, 98101 | May 3, 1990 | |
Interferon alfa-2a (recombinant) | For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma | Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07119 | May 2, 1990 | |
Anti-cytomegalovirus monoclonal antibodies | 1. human cytomegalovirus infection in bone marrow and organ transplant patients 2. Prevention of human cytomegalovirus infection in bone marrow and organ transplant patients | Biomedical Research Institute;345 North Smith Avenue;St. Paul, Minnesota, 55102 | May 2, 1990 | |
Anti-cytomegalovirus monoclonal antibodies | Prevention of human cytomegalovirus infection in bone marrow and organ transplant patients | Biomedical Research Institute;345 North Smith Avenue;St. Paul, MN, 55102 | May 2, 1990 | |
Anti-cytomegalovirus monoclonal antibodies | Human cytomegalovirus infection in bone marrow and organ transplant patients | Biomedical Research Institute;345 North Smith Avenue;St. Paul, MN, 55102 | May 2, 1990 | |
Chelmab-y or chelamusab-Y | Ovarian cancer | Cytogen Corporation;600 College Road East;Princeton, New Jersey, 08540 | April 24, 1990 | |
Fluorouracil | For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma | Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07110 | April 18, 1990 | |
N-acetylprocainamide | To lower the defibrillation energy requirement sufficiently to allow automatic implantable cardioverter defibrillator therapy in those patients who could otherwise not use the device | Medco Research, Inc.;8455 Beverly Blvd., Suite 308;Los Angeles, California, 90048 | March 23, 1990 | |
Monoclonal antibodies PM-81 and AML-2-23 | For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation | Medarex, Inc.;519 Route 173 West;Bloomsbury, New Jersey, 08804 | March 12, 1990 | |
Sucralfate suspension | Oral complications of chemotherapy in bone marrow transplant patients | Darby Pharmaceuticals, Inc.;100 Banks Avenue;Rockville Centre, New York, 11570 | March 12, 1990 | |
Thalidomide | Graft Versus Host Disease | Andrulis Research Corporation;11800 Baltimore Avenue, Suite 113;Beltsville, Maryland, 20705 | March 5, 1990 | |
Disodium clodronate tetrahydrate | Increased bone resorption due to malignancy | Anthra Pharmaceuticals, Inc.;103 Carnegie Center, Suite 102;Princeton, New Jersey, 08540 | March 5, 1990 | |
Thalidomide | Graft Versus Host Disease | Andrulis Research Corporation;11800 Baltimore Avenue, Suite 113;Beltsville, Maryland, 20705 | March 5, 1990 | |
Dextran 70 | Recurrent corneal erosion unresponsive to conventional therapy | Holles Laboratories, Inc.;30 Forest Notch;Cohasset, Massachusetts, 02025 | March 5, 1990 | |
Disaccharide tripeptide glycerol dipalmitoyl | Pulmonary and hepatic metastases in patients with colorectal adenocarcinoma | ImmunoTherapeutics, Inc.;3505 Riverview Circle;Moorhead, Minnesota, 56560 | March 1, 1990 | |
Poloxamer 188 | Severe burns requiring hospitalization | CytRx Corporation;154 Technology Parkway;Norcross, Georgia, 30092 | February 22, 1990 | |
Glyceol | To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy | Chugai Pharmaceutical Co., Ltd.;; | February 22, 1990 | |
Sermorelin acetate | Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin therapy alone | EMD Serono, Inc.;One Technology Place;Rockland, Massachusetts, 02370 | February 13, 1990 | |
Interleukin-2 | Metastatic malignant melanoma | Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07119 | February 6, 1990 | |
Indium In-111 altumomab pentetate | Detection of suspected and previously unidentified tumor foci of recurrent colorectal carcinoma | Hybritech, Inc.;11095 Torreyanna Road;San Diego, California, 92196 | February 6, 1990 | |
Dynamine | Lambert-Eaton Myasthenic Syndrome | Mayo Foundation;200 First Street Southwest;Rochester, Minnesota, 55905 | February 5, 1990 | |
Interleukin-2 | Metastatic renal cell carcinoma | Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07110 | February 5, 1990 | |
Ricin (blocked) conjugated murine MCA (anti-my9) | For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia | ImmunoGen, Inc.;830 Winter Street;Waltham, Massachusetts, 02451 | February 1, 1990 | |
PEG-interleukin-2 | Primary immunodeficiencies associated with T-cell defects | Chiron Corporation;4560 Horton Street;Emeryville, California, 94608 | February 1, 1990 | |
Melanoma vaccine | Stage III - IV melanoma | Ribi ImmunoChem Research, Inc.;533 Old Corvallis Road;Hamilton, Montana, 59840 | December 20, 1989 |